false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Moving Towards Personalized Therapy in Endometrial ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Flora Backus, a gynecologic oncologist and professor at The Ohio State University, co-chaired an educational recording titled "Towards Personalized Therapy in Endometrial Cancer." Dr. Vicky Macker from Memorial Sloan Kettering Cancer Center joined her. They discussed recent advances in endometrial cancer treatment, focusing on Selenexor maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer. The Phase III CNDOS study showed promising results, especially in patients with TP53 wild-type and MMR-proficient tumors. The ongoing EXPORT-EC042 study is evaluating Selenexor for maintenance therapy in this patient population. Dr. Macker emphasized the importance of clinical trials, personalized treatment decisions, and the evolving landscape of endometrial cancer therapy, including the role of immunotherapy.
Keywords
Dr. Flora Backus
Dr. Vicky Macker
Endometrial Cancer
Selenexor Maintenance Therapy
Clinical Trials
Contact
education@igcs.org
for assistance.
×